Nizatidine

CHEMBL3183075 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

331.5 g/mol

LogP

1.6

Phase

4

An H2 blocker that reduces stomach acid production to help heal ulcers and relieve heartburn.

Moleküler Ağırlık

331,5000 g/mol

LogP

1,60

TPSA

140,00 Å²

Lipinski RO5

Geçer

Terapötik Alanlar

Schizophrenia Gastroesophageal Reflux Disease

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

CNC(=C[N+](=O)[O-])NCCSCc1csc(CN(C)C)n1

InChI

InChI=1S/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14H,4-5,7-8H2,1-3H3

Molecular Formula

C12H21N5O2S2

HBD / HBA

2 / 8

Döndürülebilir Bağlar

9

Ağır Atomlar

21

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

An H2 blocker that reduces stomach acid production to help heal ulcers and relieve heartburn.

Yes, Nizatidine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3183075. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 4513. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Nizatidine PillFYI'da

Yapı

Hızlı Veriler

Formül: C12H21N5O2S2

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.